Establishment Labs Holdings (ESTA) EBITDA Margin (2017 - 2026)
Establishment Labs Holdings' (ESTA) quarterly EBITDA Margin came in at 10.87% in Q1 2026, up 3008.0% year-on-year from 0.35% in Q1 2025, and down 78.79% quarter-over-quarter from 6.08% in Q4 2025.
Establishment Labs Holdings (ESTA) EBITDA Margin (2017 - 2026) Analysis & Trends
Establishment Labs Holdings' EBITDA Margin history runs 10 years deep, the most recent figure standing at 10.87% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 3008.0% year-over-year to 10.87% in Q1 2026; TTM through Mar 2026 was 12.45%, a 2168.0% increase from a year earlier, with the FY2025 full-year figure at 18.48%, up 1163.0% from the prior year.
- EBITDA Margin retreated to 10.87% in Q1 2026 per ESTA's latest filing, from 6.08% in the prior quarter.
- Across five years, EBITDA Margin topped out at 6.08% in Q4 2025 and bottomed at 70.07% in Q4 2023.
- The 5-year median for EBITDA Margin is 27.5% (2022), against an average of 28.25%.
- Across the five-year window, EBITDA Margin slumped 4004 bps in 2023 and surged 3586 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 30.04% in 2022, then sank by 133 bps to 70.07% in 2023, then soared by 40 bps to 41.94% in 2024, then soared by 85 bps to 6.08% in 2025, then tumbled by 79 bps to 10.87% in 2026.
- Per Business Quant, the three latest ESTA EBITDA Margin figures stand at 10.87% (Q1 2026), 6.08% (Q4 2025), and 7.48% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Establishment Labs Holdings | 2.73 Bn | 2.66 Bn | 42.34 Mn | -10.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.87% |
| Dec 31, 2025 | -6.08% |
| Sep 30, 2025 | -7.48% |
| Jun 30, 2025 | -27.50% |
| Mar 31, 2025 | -40.96% |
| Dec 31, 2024 | -41.94% |
| Sep 30, 2024 | -32.66% |
| Jun 30, 2024 | -21.18% |
| Mar 31, 2024 | -23.77% |
| Dec 31, 2023 | -70.07% |
| Sep 30, 2023 | -54.64% |
| Jun 30, 2023 | -28.24% |
| Mar 31, 2023 | -17.54% |
| Dec 31, 2022 | -30.04% |
| Sep 30, 2022 | -27.50% |
| Jun 30, 2022 | -25.26% |
| Mar 31, 2022 | -14.50% |
| Dec 31, 2021 | -26.52% |
| Sep 30, 2021 | -31.14% |
| Jun 30, 2021 | -14.48% |